ESC/EAS 2025 Dyslipidaemia Guidelines Focused Update
In August 2025, the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)published the Focused Update of the 2019 Dyslipidaemia Guidelines, a document covering the most relevant new developments in the prevention and treatment of lipid disorders.
This article summarises the key points and new features of the 2025 ESC/EAS dyslipidaemia guidelines.
DYSLIPIDAEMIA GUIDELINES QUIZ
See how much you know!
[quiz_link tema=»guias-esc-dislipemia-2025″ target=»/realiza-el-test» results=»/resultados-del-test» text=»Hacer test» default_count=»15″]

1. Cardiovascular risk assessment: SCORE2 and SCORE2-OP
- The classic SCORE is dropped in favour of SCORE2 and SCORE2-OP, which estimate the 10-year risk of fatal and non-fatal cardiovascular events in people aged 40 to 89.
- The guidelines recommend considering risk modifiers: family history, ethnicity, chronic inflammatory disease, sleep apnoea, raised Lp(a), CAC score, etc.
- Risk should guide the intensity of LDL-C lowering.
2. LDL-C targets: "the lower, the better"
- The LDL-C targets are unchanged from 2019, but the importance of reaching them early is reinforced.
- In secondary prevention or very high risk: LDL-C <55 mg/dL and reduction ≥50%.
- In recurrent events: an even stricter target, <40 mg/dL.
3. New lipid-lowering therapies
- Bempedoic acid: useful in statin intolerance, lowers LDL-C by about 20–25% and has been shown to reduce events in the CLEAR Outcomes study.
- Evinacumab: an antibody against ANGPTL3, indicated in homozygous familial hypercholesterolaemia.
- Inclisiran: an siRNA that inhibits PCSK9, lowering LDL-C by 50%; results of morbidity and mortality trials are expected in 2026–2027.
- Their use in combination is recommended when targets are not reached.
4. Strategy in Acute Coronary Syndrome (ACS)
- Paradigm shift: "the sooner, the lower, the better".
- The guidelines recommend starting early combination therapy (high-intensity statins + ezetimibe ± PCSK9 inhibitor) during the ACS hospital admission, instead of a stepwise approach.
5. Lipoprotein(a) [Lp(a)]
- It is now established as an independent risk marker for atherosclerotic disease and aortic stenosis.
- The guidelines recommend measuring it at least once in adult life.
- Levels >50 mg/dL (105 nmol/L) should be considered an additional risk factor and may justify intensifying treatment.
- Specific drugs are in development (antisense, siRNA, oral molecules) with reductions of 80–98%.
6. Management of hypertriglyceridaemia
- Statins remain the first choice.
- Icosapent ethyl (pure EPA) (as in REDUCE-IT) should be considered in high or very high-risk patients with TG 135–499 mg/dL despite statins.
- Volanesorsen: an option for severe hypertriglyceridaemia due to familial chylomicronaemia syndrome.
7. Special populations
- Patients with HIV: REPRIEVE showed the benefit of pitavastatin (35% reduction in MACE). A statin is recommended for every patient aged ≥40, regardless of LDL-C.
- Patients with cancer at high risk of cardiotoxicity: consider statins for cardioprotection during anthracycline chemotherapy.
8. Dietary supplements
- The guidelines are clear: supplements and vitamins without proven efficacy are not recommended for reducing cardiovascular events.
- Any benefit from conventional omega-3s, garlic, turmeric, cinnamon, red yeast rice, etc. is ruled out. Evidence remains only for icosapent ethyl in selected cases.
Frequently asked questions about the 2025 ESC/EAS dyslipidaemia guidelines
1. What are the main new features of the 2025 ESC/EAS dyslipidaemia guidelines?
The key new features include the use of SCORE2/SCORE2-OP to estimate cardiovascular risk, the introduction of new drugs (bempedoic acid, evinacumab, inclisiran), early intensification of treatment after an acute coronary syndrome, the importance of measuring lipoprotein(a) and the recommendation of statins in patients with HIV or at high risk of cardiotoxicity from chemotherapy.
2. Have LDL-C targets changed in 2025?
No. The targets remain as in 2019: <55 mg/dL in secondary prevention or very high risk, and <40 mg/dL in patients with recurrent events. What changes is the recommendation to reach them as early as possible, even from the acute coronary syndrome admission.
3. What role does lipoprotein(a) [Lp(a)] have in the new guidelines?
Measuring it at least once in a lifetime is recommended. Levels >50 mg/dL (105 nmol/L) are considered an additional risk factor. Although there are no approved specific treatments yet, several drugs in development lower Lp(a) by up to 90%.
4. What do the 2025 guidelines recommend for hypertriglyceridaemia?
Statins remain first line. In high or very high-risk patients with TG of 135–499 mg/dL despite statins, icosapent ethyl can be added. For familial chylomicronaemia, volanesorsen is an option.
5. Which patients with HIV should receive statins according to the 2025 ESC/EAS guidelines?
All patients with HIV aged ≥40 in primary prevention, regardless of their LDL-C levels, should receive statins, as their cardiovascular risk is at least double that of the general population.
6. Are supplements such as omega-3, garlic or red yeast rice recommended?
No. The guidelines advise against supplements or vitamins without robust clinical evidence. Only icosapent ethyl (pure EPA) has been shown to reduce events in at-risk patients with raised triglycerides.
7. What strategy is recommended after an acute coronary syndrome?
Instead of a stepwise approach, the guidelines recommend starting early combination treatment (high-intensity statins + ezetimibe ± PCSK9 inhibitor) during the hospital admission.
Conclusion
The The 2025 ESC/EAS dyslipidaemia guidelines reinforce a strategy of:
✅ More accurate risk assessment (SCORE2).
✅ Very low LDL-C targets, reached early.
✅ Intensive, combined drug use, including new molecules.
✅ Consideration of Lp(a) and special populations (HIV, cancer).
✅ Dropping supplements without evidence.






